Biotech Values

[DewDiligence]

PPHM—AF said they would spend their time looking for funding. The deal is already done.

What deal are you referring to?

[Patrick Crutcher] has no credentials to be making any suggestions on what a cancer patient should or shouldn't do. Nor do you or [Adam Feuerstein].

That’s a silly statement. As biotech investors, we think about such questions all the time.

My guess is they will need to enroll about 300 patients before they get their answer.

Then why does today’s PR specify a trial of 600 patients?

your admitting it will take until 2016 is a step up from…[saying they] would not be able to get it enrolled.

In #msg-95399256, I said 2016 at the earliest, if they are able to do it at all. I.e. the “step-up” in my opinion is less than what you suggest.